KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Gains from Investment Securities (2017 - 2025)

Elanco Animal Health's Gains from Investment Securities history spans 9 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed 0.0% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $12.0 million, down 14.29%, while the annual FY2025 figure was $12.0 million, 14.29% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $2.0 million at Elanco Animal Health, up from -$224.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $232.0 million in Q2 2025 and bottomed at -$224.0 million in Q3 2025.
  • The 5-year median for Gains from Investment Securities is $2.0 million (2021), against an average of $1.9 million.
  • The largest YoY upside for Gains from Investment Securities was 4740.0% in 2025 against a maximum downside of 1966.67% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$9.0 million in 2021, then surged by 211.11% to $10.0 million in 2022, then decreased by 20.0% to $8.0 million in 2023, then crashed by 75.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Gains from Investment Securities are $2.0 million (Q4 2025), -$224.0 million (Q3 2025), and $232.0 million (Q2 2025).